GlaxoSmithKline (GSK) a science-led global healthcare company, will invest $139 million to expand its Rockville manufacturing site. This expansion will provide extra capacity to meet the anticipated demand for a lupus drug GlaxoSmithKline is working on.
According to a Washington Business Journal article the manufacturing site has more than 400 employees. A GSK spokeswoman said the company doesn't anticipate making any new full-time hires but may award contracts to local construction companies. GSK's investment will go toward retrofitting an existing facility at the Rockville manufacturing site. It will also cover demolition of existing suites, engineering, installation and validation of equipment.
Read more at Washington Business Journal article.